drugset
drugset / Trial / NCT07041099

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

NCT07041099 ↗

Phase 1 Recruiting 36 enrolled Cullinan Therapeutics Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Timeline

Start
2025-10-01
Primary completion
2028-03-15
Completion
2029-03-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CLN-978 Other / unclassified — Subcutaneous

Indications

Sjogren syndrome